Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the ...
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, founded on September 15, 2016, by Patrick A. Baeuerle. The company is dedicated to developing innovative therapeutics for cancer and autoimmune diseases, with a focus on immuno-oncology and T cell engagers. Its pipeline includes investigational drugs ...Cullinan Therapeutics, Inc. (NASDAQ: CGEM) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, founded on September 15, 2016, by Patrick A. Baeuerle. The company is dedicated to developing innovative therapeutics for cancer and autoimmune diseases, with a focus on immuno-oncology and T cell engagers. Its pipeline includes investigational drugs such as CLN-978, CLN-619, Zipalertinib (CLN-081/TAS6417), CLN-049, and CLN-617. The company is led by President and CEO Nadim Ahmed, who has over 25 years of leadership experience in the biotech industry. As of the latest data, Cullinan has 109 full-time employees. The company went public on January 8, 2021, and is listed on NASDAQ Global Select. Financially, Cullinan is a pre-revenue biotech, with no revenue recorded, and invests heavily in research and development. Its market capitalization is approximately $1.09 billion. The company has a strong cash position with cash per share of $5.44 and a current ratio of 8.417, indicating ample liquidity. Cullinan's culture emphasizes a people-forward approach, bringing diverse expertise to accelerate high-impact therapies. The company is committed to strategic risk-taking and rigorous decision-making to improve lives of patients with serious diseases. With a promising pipeline and a dedicated team, Cullinan aims to become a leader in developing disease-modifying therapies.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-219.9M
-31.4%
-8.1%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-175.8M
-21.0%
+17.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.7%
+80.2%
-1.1%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
10.25x
-24.3%
-18.1%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
